Bionano Genomics Announces 47% Increase in Payment Determination for OGM Use in Hematologic Malignancies.

Bionano Laboratories, a subsidiary of Bionano Genomics, announced a 47% increase in payment determination for the Category I CPT code 81195, which applies to optical genome mapping (OGM) in hematologic malignancies. The new payment rate is $1853.22, up from $1263.53, effective January 1, 2026. This increase is expected to make it easier to offer OGM-based LDTs for hematologic malignancies and raise awareness of the utility of OGM in the oncology and clinical genetic testing communities.